Keller S M
Department of Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, New York.
Chest Surg Clin N Am. 1994 Feb;4(1):127-35.
Patients with malignant pleural mesothelioma appear to have gained little benefit from even the most intensive multimodality therapy. Although the reported median survival of patients who undergo some surgical procedure as part of their therapy appears to be superior to that of those patients treated in a nonoperative fashion, the lack of a randomized trial renders these data suspect. New approaches, perhaps consisting of biologic response modifiers, more effective chemotherapy, and innovative methods that achieve improved local disease control, are needed.
恶性胸膜间皮瘤患者似乎从即使是最强化的多模式治疗中获益甚微。尽管据报道，接受某种手术作为治疗一部分的患者的中位生存期似乎优于那些接受非手术治疗的患者，但由于缺乏随机试验，这些数据令人怀疑。需要新的方法，可能包括生物反应调节剂、更有效的化疗以及能改善局部疾病控制的创新方法。
